Inmed PharmaceuticalsINM
13F holders, Q4 2025 (December 31)7holders −2
3new positions
4sold out
$1.06avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Inmed Pharmaceuticals Inc. (INM) in their 13F filings, down 2 from Q3 2025. 3 opened new positions and 4 sold out. The largest holders were Sabby Management, LLC ($214K), Susquehanna International Group, LLP ($14K) and Jane Street Group, LLC ($13K).
- Company
- Inmed Pharmaceuticals Inc.
- CUSIP
- 457637700
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $27K |
| Exits | 4 | $183K |
All 13F filers, Q3 2025 → Q4 2025: 25,108 shares bought and 101,648 shares sold, net −76,540 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Sabby Management, LLC | 1.79% | Reduce -8.3% | 201,633 | $214K |
| Susquehanna International Group, LLP | 0.00% | New | 12,753 | $14K |
| Jane Street Group, LLC | 0.00% | New | 11,978 | $13K |
| UBS Group AG | 0.00% | New | 377 | $400 |
| SBI Securities Co., Ltd. | 0.00% | No change | 300 | $318 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 2 | $2 |
| Banque Cantonale Vaudoise | 0.00% | No change | 6 | $0 |
"% of holder's portfolio" is INM's weight in each manager's 13F, not the share of Inmed Pharmaceuticals Inc. the manager owns.